EdgarLookup

SANFILIPPO JOHN B & SON INC — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that SANFILIPPO JOHN B & SON INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
5.3%
Profit Margin
Net income ÷ revenue
9.9%
Return on Assets
Net income ÷ assets
0.66x
Debt-to-Equity
Total liabilities ÷ equity
+3.8%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 $1.11B Aug 20, 2025
FY2025 Jun 27, 2024 $1.07B Aug 20, 2025
FY2025 Jun 29, 2023 $999.69M Aug 20, 2025
FY2024 Jun 30, 2022 $955.87M Aug 21, 2024
FY2023 Jun 24, 2021 $858.48M Aug 23, 2023
FY2022 Jun 25, 2020 $880.09M Aug 24, 2022
FY2021 Jun 27, 2019 $876.20M Aug 18, 2021

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2021 Jun 24, 2021 $206.74M Aug 18, 2021
FY2021 Mar 25, 2021 $207.89M Aug 18, 2021
FY2021 Dec 25, 2020 $233.58M Aug 18, 2021
FY2021 Sep 25, 2020 $210.27M Aug 18, 2021
FY2021 Jun 25, 2020 $204.20M Aug 18, 2021
FY2021 Mar 26, 2020 $211.62M Aug 18, 2021
FY2021 Dec 26, 2019 $246.42M Aug 18, 2021
FY2021 Sep 26, 2019 $217.85M Aug 18, 2021
FY2020 Jun 27, 2019 $216.76M Aug 19, 2020
FY2020 Mar 28, 2019 $201.83M Aug 19, 2020

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 $203.47M Aug 20, 2025
FY2025 Jun 27, 2024 $214.14M Aug 20, 2025
FY2025 Jun 29, 2023 $211.63M Aug 20, 2025
FY2024 Jun 30, 2022 $199.63M Aug 21, 2024
FY2021 Jun 24, 2021 $46.81M Aug 18, 2021
FY2021 Mar 25, 2021 $46.05M Aug 18, 2021
FY2021 Dec 25, 2020 $52.80M Aug 18, 2021
FY2021 Sep 25, 2020 $39.33M Aug 18, 2021
FY2021 Jun 25, 2020 $40.74M Aug 18, 2021
FY2021 Mar 26, 2020 $42.81M Aug 18, 2021

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 $58.93M Aug 20, 2025
FY2025 Jun 27, 2024 $60.25M Aug 20, 2025
FY2025 Jun 29, 2023 $62.86M Aug 20, 2025
FY2024 Jun 30, 2022 $61.79M Aug 21, 2024
FY2021 Jun 24, 2021 $12.34M Aug 18, 2021
FY2021 Mar 25, 2021 $14.70M Aug 18, 2021
FY2021 Dec 25, 2020 $19.89M Aug 18, 2021
FY2021 Sep 25, 2020 $12.81M Aug 18, 2021
FY2021 Jun 25, 2020 $10.26M Aug 18, 2021
FY2021 Mar 26, 2020 $13.47M Aug 18, 2021

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 $84.71M Aug 20, 2025
FY2025 Jun 27, 2024 $85.19M Aug 20, 2025
FY2025 Jun 29, 2023 $90.22M Aug 20, 2025
FY2024 Jun 30, 2022 $87.44M Aug 21, 2024
FY2021 Jun 24, 2021 $17.41M Aug 18, 2021
FY2021 Mar 25, 2021 $21.10M Aug 18, 2021
FY2021 Dec 25, 2020 $27.80M Aug 18, 2021
FY2021 Sep 25, 2020 $18.87M Aug 18, 2021
FY2021 Jun 25, 2020 $15.62M Aug 18, 2021
FY2021 Mar 26, 2020 $19.40M Aug 18, 2021

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 $3.49M Aug 20, 2025
FY2025 Jun 27, 2024 $3.62M Aug 20, 2025
FY2025 Jun 29, 2023 $3.36M Aug 20, 2025
FY2024 Jun 30, 2022 $2.83M Aug 21, 2024
FY2023 Jun 24, 2021 $2.00M Aug 23, 2023
FY2022 Jun 25, 2020 $999.0K Aug 24, 2022
FY2021 Jun 27, 2019 $892.0K Aug 18, 2021
FY2020 Jun 28, 2018 $701.0K Aug 19, 2020
FY2019 Jun 29, 2017 $658.0K Aug 21, 2019
FY2018 Jun 30, 2016 $653.0K Aug 22, 2018

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 $30.55M Aug 20, 2025
FY2025 Jun 27, 2024 $101.67M Aug 20, 2025
FY2025 Jun 29, 2023 $124.66M Aug 20, 2025
FY2024 Jun 30, 2022 $19.60M Aug 21, 2024
FY2023 Jun 24, 2021 $104.70M Aug 23, 2023
FY2022 Jun 25, 2020 $63.61M Aug 24, 2022
FY2021 Jun 27, 2019 $83.46M Aug 18, 2021
FY2020 Jun 28, 2018 $66.15M Aug 19, 2020
FY2019 Jun 29, 2017 $52.67M Aug 21, 2019
FY2018 Jun 30, 2016 $89.25M Aug 22, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 $50.71M Aug 20, 2025
FY2025 Jun 27, 2024 $28.31M Aug 20, 2025
FY2025 Jun 29, 2023 $20.73M Aug 20, 2025
FY2024 Jun 30, 2022 $17.75M Aug 21, 2024
FY2023 Jun 24, 2021 $25.18M Aug 23, 2023
FY2022 Jun 25, 2020 $15.02M Aug 24, 2022
FY2021 Jun 27, 2019 $15.08M Aug 18, 2021
FY2020 Jun 28, 2018 $13.23M Aug 19, 2020
FY2019 Jun 29, 2017 $10.89M Aug 21, 2019
FY2018 Jun 30, 2016 $15.02M Aug 22, 2018

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 $597.60M Aug 20, 2025
FY2025 Jun 27, 2024 $515.58M Aug 20, 2025
FY2024 Jun 29, 2023 $425.29M Aug 21, 2024
FY2023 Jun 30, 2022 $447.26M Aug 23, 2023
FY2022 Jun 24, 2021 $398.46M Aug 24, 2022
FY2021 Jun 25, 2020 $407.46M Aug 18, 2021
FY2020 Jun 27, 2019 $391.30M Aug 19, 2020
FY2019 Jun 28, 2018 $415.85M Aug 21, 2019
FY2018 Jun 29, 2017 $398.06M Aug 22, 2018
FY2017 Jun 30, 2016 $391.16M Aug 23, 2017

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 $236.91M Aug 20, 2025
FY2025 Jun 27, 2024 $192.96M Aug 20, 2025
FY2024 Jun 29, 2023 $133.08M Aug 21, 2024
FY2023 Jun 30, 2022 $168.44M Aug 23, 2023
FY2022 Jun 24, 2021 $155.96M Aug 24, 2022
FY2021 Jun 25, 2020 $169.22M Aug 18, 2021
FY2020 Jun 27, 2019 $136.75M Aug 19, 2020
FY2019 Jun 28, 2018 $172.85M Aug 21, 2019
FY2018 Jun 29, 2017 $162.59M Aug 22, 2018
FY2017 Jun 30, 2016 $139.97M Aug 23, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 $360.70M Aug 20, 2025
FY2025 Jun 27, 2024 $322.61M Aug 20, 2025
FY2025 Jun 29, 2023 $292.21M Aug 20, 2025
FY2025 Jun 30, 2022 $278.82M Aug 20, 2025
FY2024 Jun 24, 2021 $242.49M Aug 21, 2024
FY2023 Jun 25, 2020 $238.24M Aug 23, 2023
FY2022 Jun 27, 2019 $254.56M Aug 24, 2022
FY2021 Jun 28, 2018 $243.00M Aug 18, 2021
FY2020 Jun 29, 2017 $235.47M Aug 19, 2020
FY2019 Jun 30, 2016 $251.19M Aug 21, 2019

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 $11.75M Aug 20, 2025
FY2025 Jun 27, 2024 $11.75M Aug 20, 2025
FY2025 Jun 29, 2023 $11.75M Aug 20, 2025
FY2024 Jun 30, 2022 $9.65M Aug 21, 2024
FY2023 Jun 25, 2021 $9.65M Aug 23, 2023
FY2022 Jun 24, 2021 $9.65M Aug 24, 2022
FY2022 Jun 26, 2020 $9.65M Aug 24, 2022
FY2021 Jun 25, 2020 $9.65M Aug 18, 2021
FY2021 Jun 28, 2019 $9.65M Aug 18, 2021
FY2020 Jun 27, 2019 $9.65M Aug 19, 2020

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 $221.50M Aug 20, 2025
FY2025 Jun 27, 2024 $186.97M Aug 20, 2025
FY2024 Jun 29, 2023 $161.51M Aug 21, 2024
FY2023 Jun 30, 2022 $153.59M Aug 23, 2023
FY2022 Jun 24, 2021 $126.34M Aug 24, 2022
FY2021 Jun 25, 2020 $124.06M Aug 18, 2021
FY2020 Jun 27, 2019 $137.71M Aug 19, 2020
FY2019 Jun 28, 2018 $127.32M Aug 21, 2019
FY2018 Jun 29, 2017 $123.19M Aug 22, 2018
FY2017 Jun 30, 2016 $143.57M Aug 23, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 $585.0K Aug 20, 2025
FY2025 Jun 27, 2024 $484.0K Aug 20, 2025
FY2024 Jun 29, 2023 $1.95M Aug 21, 2024
FY2023 Jun 30, 2022 $415.0K Aug 23, 2023
FY2022 Jun 24, 2021 $672.0K Aug 24, 2022
FY2021 Jun 25, 2020 $1.54M Aug 18, 2021
FY2020 Jun 27, 2019 $1.59M Aug 19, 2020
FY2019 Jun 28, 2018 $1.45M Aug 21, 2019
FY2018 Jun 29, 2017 $1.96M Aug 22, 2018
FY2017 Jun 30, 2016 $2.22M Aug 23, 2017

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2013 Jun 27, 2013 $42.36M Aug 28, 2013
FY2012 Jun 28, 2012 $48.93M Aug 30, 2012

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 5 Aug 20, 2025
FY2025 Jun 27, 2024 5 Aug 20, 2025
FY2025 Jun 29, 2023 5 Aug 20, 2025
FY2024 Jun 30, 2022 5 Aug 21, 2024
FY2021 Jun 24, 2021 1 Aug 18, 2021
FY2021 Mar 25, 2021 1 Aug 18, 2021
FY2021 Dec 25, 2020 1 Aug 18, 2021
FY2021 Sep 25, 2020 1 Aug 18, 2021
FY2021 Jun 25, 2020 0 Aug 18, 2021
FY2021 Mar 26, 2020 1 Aug 18, 2021

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Jun 26, 2025 5 Aug 20, 2025
FY2025 Jun 27, 2024 5 Aug 20, 2025
FY2025 Jun 29, 2023 5 Aug 20, 2025
FY2024 Jun 30, 2022 5 Aug 21, 2024
FY2021 Jun 24, 2021 1 Aug 18, 2021
FY2021 Mar 25, 2021 1 Aug 18, 2021
FY2021 Dec 25, 2020 1 Aug 18, 2021
FY2021 Sep 25, 2020 1 Aug 18, 2021
FY2021 Jun 25, 2020 0 Aug 18, 2021
FY2021 Mar 26, 2020 1 Aug 18, 2021